BusinessNews Pulse
Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch - MedCity News
Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. Thi…
Read the full pulseContinue in Briflio to read, react, comment, and share.
Sources